Understanding Artificial Pancreas Systems: Results from a 24-Month Trial

Related and Discussions

Subscribe now for the latest breakthroughs, expert insights, and cutting-edge updates in diabetes care—delivered straight to your inbox.

Stay informed. Stay ahead.

Four studies showed DPP-4 inhibitors had no clear effect on new diabetic eye disease compared to other diabetes medications. Individual results were mixed, with most showing no difference. The finding suggests these medications neither increase nor decrease eye disease risk. Limited evidence rating reflects the observational study design, variation between studies, and reliance on diagnosis codes rather than detailed eye exams.

Three studies found no clear effect of DPP-4 inhibitors on worsening existing eye disease. Results were inconsistent across studies, with one small study showing reduced worsening, one large study showing increased worsening, and one showing no effect. Limited evidence rating reflects the small number of studies, wide variation in results, different definitions of worsening, and observational design.

These findings differ somewhat from a previous analysis of clinical trials, which suggested DPP-4 inhibitors might increase eye disease risk. However, the difference likely reflects the controlled trial setting versus real-world use captured in observational studies.

Two large trials called TECOS and CARMELINA found similar results to this review, showing no clear increase in eye problems with DPP-4 inhibitors. A small study even suggested potential benefits for eye blood flow. Laboratory research shows conflicting results about how these medications might affect eye tissue. Other diabetes medications like SGLT2 inhibitors and GLP-1 drugs also appear neutral for eye disease risk.

The moderate confidence rating reflects some important limitations. These were observational studies of routine care, not controlled trials, so other factors could influence the results. Eye disease was identified mainly through medical records rather than detailed eye exams, which may miss some cases. Most studies followed people for only 2-3 years, which may not be long enough to see all effects. Results varied considerably between studies. Despite these limitations, the consistent finding of no major effect across multiple countries supports the overall conclusion.

DPP-4 inhibitors do not appear to increase or decrease the risk of developing diabetic eye disease

DPP-4 inhibitors show no clear effect on worsening of existing eye disease

Results were similar across different countries, though individual studies showed some variation

DPP-4 inhibitors appear neutral for eye disease risk, neither helping nor harming compared to other diabetes medications

The evidence is most reassuring that these medications don't increase eye disease risk, which is good news for current users

Findings are limited by reliance on medical records rather than comprehensive eye exams and relatively short follow-up

Individual studies showed mixed results, highlighting uncertainty around small effects that might exist

The studied group included people with type 2 diabetes taking DPP-4 inhibitors, a class of diabetes pills that work by affecting hormones involved in blood sugar control. These medications include sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and gemigliptin. They can be used alone or with other diabetes medications.

Most studies required people to be on the medication for at least 3-6 months. These pills are often used when first-line medications aren't enough, and they typically don't cause weight gain or low blood sugar. Comparison groups included people taking other diabetes medications like sulfonylureas, metformin, or thiazolidinediones.

Dipeptidyl peptidase-4 inhibitors, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, gemigliptin, oral hypoglycemic agents, incretin enhancers

Wang M, Lu J, Dong J. Association between dipeptidyl peptidase-4 inhibitor use and diabetic retinopathy: a systematic review and meta-analysis of real-world studies. BMC Ophthalmol. 2024;24:272. doi:10.1186/s12886-024-03535-1

Seven studies found no clear difference in eye disease risk between people taking DPP-4 inhibitors and those on other diabetes medications. For new eye disease cases, four studies showed DPP-4 inhibitors neither increased nor decreased risk. For worsening of existing eye disease, three studies again showed no clear difference. Individual study results were mixed, with most showing no effect either way. Results varied considerably between studies, which may reflect differences in patient groups or how eye disease was measured.

Eye disease identified through records, not comprehensive exams

Short follow-up in most studies (2-3 years)

Observational design limits certainty about cause and effect

DPP-4 inhibitors appear safe for diabetic eye disease, showing no increased risk.

Studies relied on medical records rather than direct assignment of medications, which could introduce bias in who received which treatment. Eye disease was identified mainly through diagnosis codes, not comprehensive eye exams, potentially missing less severe cases. Follow-up lasted only 2-3 years in most studies, which may not capture long-term effects. Results varied widely between studies, suggesting important differences in how they were conducted or who was included. Information on blood sugar control, medication adherence, and how long people took DPP-4 inhibitors was often unavailable. Comparison groups differed across studies, making it hard to draw firm conclusions. Two studies from Korea may have included some of the same people.

New diabetic eye disease → → (no clear change)

Worsening existing eye disease → → (no clear change)

Green JB et al., New England Journal of Medicine

TECOS Trial - Sitagliptin and Cardiovascular Outcomes

CARMELINA Trial - Linagliptin Cardiovascular Safety

Global prevalence and major risk factors of diabetic retinopathy

Researchers searched five major medical databases through July 2023 for studies comparing DPP-4 inhibitor users with non-users. They included seven observational studies from Taiwan, Korea, Germany, the USA, and Denmark. Study sizes ranged from 48 to over 126,000 people with type 2 diabetes. Average participant age was 57-77 years, with diabetes lasting 3-8 years in most cases.

Eye disease was identified mainly through diagnosis codes in medical records, with one study using detailed grading scales. Follow-up ranged from 2 to 10 years. Four studies used matching techniques to make the groups more similar. Two reviewers independently checked study quality. The team combined results from all studies while accounting for differences between them.

DPP-4 inhibitors show no clear effect on diabetic eye disease risk

This review looked at whether DPP-4 inhibitors, a type of diabetes pill, affect the risk of diabetic eye disease. Researchers analyzed seven studies involving people with type 2 diabetes from several countries. The results showed no clear difference in eye disease risk between people taking DPP-4 inhibitors and those on other diabetes medications. This finding was consistent across different groups, though individual study results varied.

These were routine care studies, not controlled trials, so other differences between groups could affect results

Eye disease was identified through medical codes, potentially missing milder cases or misclassifying some people

Effects beyond 2-3 years remain uncertain, and differences between specific DPP-4 inhibitor types could not be determined

7 studies tracking eye disease in people with type 2 diabetes taking DPP-4 inhibitors

Adults with type 2 diabetes taking oral medications, especially those considering DPP-4 inhibitors

Adults with type 2 diabetes treated with oral hypoglycemic medications, particularly those considering or currently using DPP-4 inhibitors

DPP-4 inhibitors show no clear effect on diabetic eye disease risk

Study at a glance

What was studied

What they found

mainEffects

Evidence Suggest

Who this applies to

Keep in Mind

Between the Lines

Unlock Full Analysis

No ads. No tracking

Secure & private

Always up to date